Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05452772 · ClinicalTrials.gov registry record · Phase 2
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
A Phase 2 study of Tobacco Use Disorder, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 3
- Study locations
NCT05452772 is a Phase 2 study of Tobacco Use Disorder that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 66 participants, below the 238-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (72% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05452772, a Phase 2 study of Tobacco Use Disorder, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist psilocybin for smoking cessation. Four sites with experience in conducting psilocybin research will be involved in this trial: Johns Hopkins University (JHU), the University of Alabama at Birmingham (UAB), and New York University (NYU). The proposed study will treat 66 participants (22 at each site), randomized to receive either: 1) oral psilocybin (30 mg in session 1 and either 30 mg or 40 mg in session 2); or 2) oral niacin (150 mg in session 1 and either 150 mg or 200 mg in session 2), with sessions 1 week apart.
Conditions Studied
Interventions
- DRUG Niacin
- DRUG Psilocybin
Study Locations (3)
Alabama
- University of Alabama at Birmingham - Birmingham
Maryland
- Johns Hopkins University School of Medicine - Baltimore
New York
- New York University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05452772
The ClinicalTrials.gov registry entry for NCT05452772 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (72% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tobacco Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Niacin is the first listed.
NCT05452772 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Alabama, Maryland, New York.
Frequently Asked Questions
What is clinical trial NCT05452772 about?
NCT05452772 is a clinical study titled "5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder". This is a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist psilocybin for smoking cessation. Four sites with experience in conducting psilocybin research will be involved in this trial: Johns Hopkins University (JHU), the University of Alabama at Birmingham (UAB), a...
What is the current status of trial NCT05452772?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2023-11-01. Estimated completion is 2027-05.
What conditions does trial NCT05452772 study?
This clinical trial studies the following conditions: Tobacco Use Disorder.
What interventions are being tested in trial NCT05452772?
The interventions under investigation include: Niacin (DRUG), Psilocybin (DRUG).
Who is sponsoring clinical trial NCT05452772?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05452772 being conducted?
This trial has 3 study locations across Alabama, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
RECRUITING · Phase 2
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Cannabidiol for Reducing Cigarette Use
RECRUITING · Phase 2
-
An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction
RECRUITING · Phase 2
-
Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.